- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
| 20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
| 13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
| 13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 217 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
| 15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
| 15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 243 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| 14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
| 14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 225 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics GAAP EPS of -$0.46 | 1 | Seeking Alpha | ||
| 13.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 789 | PR Newswire | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,648 | -0,38 % | Valneva Aktie zündet nach Impfstoff-News - oder doch nur ein Strohfeuer? | Die Valneva Aktie reagierte am Montag mit einem Kurssprung auf die Meldung, dass die Europäische Arzneimittel-Agentur EMA nach positiver Prüfung die Altersbeschränkung für den Chikungunya-Impfstoff... ► Artikel lesen | |
| BIOFRONTERA | 2,450 | +1,24 % | Biofrontera files to sell 13.6M shares of common stock by selling shareholders | ||
| CRISPR THERAPEUTICS | 57,50 | +2,68 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| DENALI THERAPEUTICS | 11,720 | -0,97 % | Denali Therapeutics Inc.: Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome | SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,995 | +1,59 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| CELLECTIS | 1,502 | -0,40 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
| AGIOS | 34,800 | +1,75 % | Avanzanite Bioscience B.V.: Avanzanite gibt europaweite Partnerschaft mit Agios zur Einführung von PYRUKYND bei seltenen Blutgerinnungsstörungen bekannt | PYRUKYND® (Mitapivat) ist der erste und einzige Pyruvatkinase (PK)-Aktivator, der von der Europäischen Kommission für Erwachsene mit PK-Mangel zugelassen ist
Die Vereinbarung umfasst die... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,674 | -1,26 % | Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach | - New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly-owned... ► Artikel lesen | |
| UNIQURE | 13,175 | +6,25 % | uniQure Inc.: uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer | ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~
LEXINGTON, Mass. and AMSTERDAM, June 11, 2025N.V. (NASDAQ: QURE), a leading gene therapy company advancing... ► Artikel lesen | |
| ENZO BIOCHEM | 0,580 | 0,00 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
| SCILEX | 8,600 | -2,93 % | Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule | PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 21,965 | 0,00 % | Truist Securities initiates Tectonic Therapeutics stock with Buy rating | ||
| ALLOGENE THERAPEUTICS | 1,325 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS = 50% Advanced or... ► Artikel lesen |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 21,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.